Obstetrical and Neonatal Outcome following Clonazepam Use during Pregnancy: A Case Series

  title={Obstetrical and Neonatal Outcome following Clonazepam Use during Pregnancy: A Case Series},
  author={Lisa Weinstock and Lee S. Cohen and Jennie W. Bailey and Robert N. Blatman and Jerrold F. Rosenbaum},
  journal={Psychotherapy and Psychosomatics},
  pages={158 - 162}
Background: Given the high prevalence of panic disorder in women, treatment decisions are frequently made regarding the use of anti-panic medications during the childbearing years and during pregnancy. The objective of this case series was to evaluate obstetric and neonatal outcome associated with treatment with clonazepam during pregnancy. Methods: Subjects were 38 women with histories of panic disorder who used clonazepam during pregnancy. Information regarding the amount and duration of… 
Clonazepam use in pregnancy and the risk of malformations.
This study did not observe an increase in major malformations in births exposed to clonazepam monotherapy, and the number of patients in this series was larger than previous reports, so continued monitoring of pregnancies is needed to determine whether or not clonzepam is teratogenic.
Management of bipolar disorder during pregnancy and the postpartum period.
Since treatment can be managed most effectively if pregnancy is planned, clinicians should discuss the issue of pregnancy and its management with every bipolar disorder patient who has childbearing potential, regardless of future reproductive plans.
Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects
This narrative review is aimed at the description of drugs and drug classes for which licit maternal use in the predelivery period has been associated with neonatal non-teratogenic disorders, mainly for substances used illicitly for recreational purposes.
Management of Bipolar Disorder During Pregnancy The Postpartum Period
The authors summarize knowledge regarding the management of bipolar disorder during pregnancy and the postpartum period, with a focus on managing mania, hypomania, and the psychotic components of the illness.
The safety of medications for the treatment of bipolar disorder during pregnancy and the puerperium.
There have been an insufficient number of first trimester exposures to the newer anticonvulsant mood stabilisers, lamotrigine and oxcarbazepine, to determine whether there is a safety advantage in switching to these agents.
Psychopharmacologic Strategies for Women to Plan Pregnancy
Clinicians are faced with major challenges when treating women with psychiatric disorders who are contemplating pregnancy or are pregnant, and clinical considerations for the interventions such as family planning, parental education and supporting, and antenatal care are important to reduce the risk of pregnancy complications.
Psychopharmacological treatment of mood and anxiety disorders during pregnancy.
  • S. Krüger
  • Medicine, Psychology
    Handbook of experimental pharmacology
  • 2012
This presentation is intended to assist in understanding the general principles of pharmacotherapy during pregnancy as well as the morphological, perinatal and neurobehavioural toxicity of antidepressants, antipsychotics, benzodiazepines and mood stabilisers.
Obstetrics and Gynecology Patients: Menstrual Cycle, Pregnancy, and Postpartum-Related Psychiatric Disorders
Pregnancy and the postpartum period are considered to be vulnerable times in a woman’s life with significant increase and drop in reproductive hormones and increased risk of psychiatric symptoms.


Neonatal Apnea Associated With Maternal. Clonazepam Therapy: A Case Report
The authors suggest that infants of mothers receiving this agent during pregnancy or while nursing have serum levels measured, and these infants should be monitored for central nervous system depression or apnea.
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
Exposure to certain psychotropic drugs in utero may increase the risk for some specific congenital anomalies, but the rate of occurrence of these anomalies even with the increased risk remains low.
Impact of pregnancy on panic disorder: a case series.
Impact of pregnancy on panic disorder is variable; some patients, particularly those with milder symptoms, may improve during this time; more severely ill women may constitute a subgroup at risk for persistence of underlying disease and with a need for continued treatment with antipanic medication.
Panic disorder in pregnancy.
It is suggested that pregnancy may have a highly variable influence on the course of panic disorder, and postpartum worsening of panic may be a more consistent phenomenon.
Effect of maternal lorazepam on the neonate.
The effects of lorazepam on neonates indicate that its intravenous use at any stage in pregnancy and oral use before 37 weeks should be restricted to hospitals with facilities for neonatal intensive care.
Maternal anxiety in late pregnancy and fetal hemodynamics.
Anxiety and epinephrine in multiparous women in labor: relationship to duration of labor and fetal heart rate pattern.
The results suggest that medical/nursing evaluation and management of patient anxiety should include a self-report measure of three dimensions of anxiety, which are relatively independent of observed physical stress and which may relate to maternal labor progress as well as fetal heart rate pattern.
Psychotropic drug use in pregnancy.
  • L. Cohen
  • Medicine, Psychology
    Hospital & community psychiatry
  • 1989
Until better controlled studies evaluating both teratogenic effects and long-term toxic consequences of exposure to psychotropic drugs in utero or through breast milk are available, women who are pregnant or plan to become pregnant and nursing mothers must be individually evaluated.
The longitudinal course and outcome of panic disorder.